Zeldox and Zyprexa IM formulations

FDA Psychopharmacologic Drugs Advisory Committee will review intramuscular formulations of Lilly's Zyprexa (olanzapine) and Pfizer's Zeldox (ziprasidone) for use in schizophrenia during February meeting. Zyprexa, which is already marketed in an oral formulation, will be reviewed on Feb. 14. Zeldox, which is "approvable" at FDA in an oral formulation, will be reviewed on the second day. The meeting will take place at the Holiday Inn-Gaithersburg, Md., beginning at 8 a.m. both days